← Back to Clinical Trials
Recruiting NCT04424719
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
Trial Parameters
Condition Uveal Melanoma
Sponsor Institut Curie
Study Type INTERVENTIONAL
Phase N/A
Enrollment 700
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2020-07-08
Completion 2037-07-07
Interventions
Blood test
Brief Summary
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
Eligibility Criteria
Inclusion Criteria: 1. Patient aged of 18 years or more. 2. Patient with uveal melanoma with high metastatic relapse risk defined as : * T2b/c/d ou ≥ T3, * or chromosom 3 or chromosom 8 abnormality by CGH array. 3. Completion of treatment of the primary tumor ≤ 2 months. 4. Patient able to comply with the schedule of visits and blood samples of the study. 5. Signed informed consent form or legal representative. Exclusion Criteria: 1. Patient without french social insurance. 2. Any social, medical or psychological condition making the research process impossible.
Related Trials
NCT04119024
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
View Trial →
NCT07421739
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subje
View Trial →
NCT04424719
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
View Trial →